S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   299.19 (+0.98%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.60 (+0.73%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,196.00 (+0.34%)
TSLA   585.16 (+1.94%)
NVDA   530.10 (+0.13%)
BABA   276.50 (-0.44%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.07 (+1.01%)
AMD   87.17 (+0.53%)
T   29.03 (+0.14%)
NIO   53.88 (+0.35%)
F   9.10 (+0.22%)
ACB   10.55 (+21.13%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
OTCMKTS:CVSI

CV Sciences Stock Forecast, Price & News

$0.43
-0.03 (-6.52 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.40
Now: $0.43
$0.46
50-Day Range
$0.45
MA: $0.48
$0.54
52-Week Range
$0.25
Now: $0.43
$1.34
Volume1.03 million shs
Average Volume527,729 shs
Market Capitalization$43.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
CV Sciences, Inc. operates as a life science company. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets hemp-based cannabidiol (CBD) products under the name of PlusCBD in a range of market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. Its products product candidates are based on proprietary formulations, processes, and technology. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CVSI
Previous SymbolNASDAQ:CVSI
CUSIPN/A
Phone866-290-2157
Employees118

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.70 million
Book Value$0.19 per share

Profitability

Net Income$-16,610,000.00

Miscellaneous

Market Cap$43.24 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$0.43
-0.03 (-6.52 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

How has CV Sciences' stock price been impacted by Coronavirus (COVID-19)?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVSI stock has decreased by 28.3% and is now trading at $0.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CV Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CV Sciences
.

What stocks does MarketBeat like better than CV Sciences?

Wall Street analysts have given CV Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CV Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for CV Sciences
.

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The business had revenue of $5.56 million for the quarter, compared to analysts' expectations of $6.32 million. CV Sciences had a negative return on equity of 81.99% and a negative net margin of 68.90%.
View CV Sciences' earnings history
.

What price target have analysts set for CVSI?

4 analysts have issued 12-month price objectives for CV Sciences' stock. Their forecasts range from $0.75 to $1.70. On average, they expect CV Sciences' stock price to reach $1.13 in the next twelve months. This suggests a possible upside of 163.6% from the stock's current price.
View analysts' price targets for CV Sciences
.

Who are some of CV Sciences' key competitors?

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), Aphria (APHA), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:
  • Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 63, Pay $708.77k)
  • Mr. Joerg Grasser, Chief Financial Officer (Age 45, Pay $389.23k)
  • Dr. Douglas Jesse MacKay ND, Sr. VP of Scientific & Regulatory Affairs (Age 47)

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.43.

How big of a company is CV Sciences?

CV Sciences has a market capitalization of $43.24 million and generates $53.70 million in revenue each year. The company earns $-16,610,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. CV Sciences employs 118 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.